source
- Par Health recalls two lots of Brevital Sodium injection over cellulose particlesPar Health announced a voluntary recall of two lots of its Brevital® Sodium 500 mg/vial for injection after detecting particulate matter identified as cellulose. The recall is being executed at th…
- Aspen Neuroscience and Bambusa Therapeutics announce plans to go public amid biotech IPO surgeAspen Neuroscience, a cell therapy company backed by Gilead, and Bambusa Therapeutics, an I&I biotech founded by former BioNTech scientists, have each filed paperwork to launch initial public offer…